Financial Performance - The company's operating revenue for Q1 2025 was ¥63,743,551.35, a decrease of 15.53% compared to ¥75,460,849.87 in the same period last year[5] - The net loss attributable to shareholders was ¥45,174,602.67, representing a 10.58% increase from a loss of ¥40,853,954.75 in the previous year[5] - Basic and diluted earnings per share were both -¥0.0678, reflecting a decrease of 10.60% from -¥0.0613 in the same quarter last year[5] - Operating profit for the current period is -¥52,695,244.21, compared to -¥50,350,649.71 in the previous period, indicating a slight increase in losses[24] - Net profit for the current period is -¥62,769,455.79, compared to -¥60,502,670.21 in the previous period, reflecting a worsening of approximately 3.8%[24] - The total comprehensive loss amounted to -62,769,455.79 CNY, slightly higher than the previous period's loss of -60,502,670.21 CNY, reflecting an increase of about 3.8%[25] Cash Flow and Liquidity - The net cash flow from operating activities was -¥10,598,571.43, a significant decline of 1,087.19% compared to a positive cash flow of ¥1,073,613.47 in the prior year[5] - Cash inflows from operating activities totaled 50,142,889.64 CNY, down from 78,413,126.79 CNY in the previous period, a decline of about 36.0%[27] - Cash and cash equivalents decreased from ¥24,509,161.98 to ¥15,756,568.83, a decline of about 35.5%[20] - Cash and cash equivalents at the end of the period were 7,789,702.73 CNY, significantly lower than 26,700,040.88 CNY at the end of the previous period, a decrease of approximately 70.8%[29] - The net cash flow from financing activities was 1,857,433.37 CNY, down from 3,021,352.18 CNY in the previous period, indicating a decline of about 38.5%[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,428,970,156.95, down 1.08% from ¥1,444,512,507.38 at the end of the previous year[5] - Total liabilities increased from ¥2,947,890,187.24 to ¥2,996,904,097.04, an increase of about 1.7%[21] - The company has a negative retained earnings of -¥3,060,755,075.42, worsening from -¥3,015,580,472.75 in the previous period[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,056, with the top ten shareholders holding a combined total of 38,364,481 shares[10] - The top ten shareholders hold a total of 9,487,015 shares, representing 0.83% of the total shares outstanding[11] - The company has not disclosed any changes in the participation of major shareholders in margin financing or securities lending activities[12] - The company has not identified any related party relationships among the top ten shareholders[11] - The company has a total of 4,605,450 restricted shares held by other shareholders, with 2,550 shares released during the period[14] - As of March 31, 2025, the company reported a significant increase in restricted shares, totaling 21,913,249 shares, up from 12,768,750 shares[14] Operational Challenges - The company reported a significant decrease in cash received from sales, totaling ¥37,979,527.05, down 44.29% from ¥68,171,452.73 in the previous year[9] - Sales expenses increased by 64.20% to ¥10,976,344.75, primarily due to increased sales promotion efforts during the reporting period[9] - The company recorded a government subsidy of ¥128,842.82, a decrease of 57.99% from ¥306,713.63 in the previous year[9] - The company faces a significant delisting risk as its stock price has been below 1 RMB for twenty consecutive trading days, leading to a notice from the Shenzhen Stock Exchange regarding the termination of its stock listing[17] - The company has initiated a bankruptcy reorganization process to alleviate historical debt pressure and restore profitability, with the court approving the pre-reorganization on November 27, 2023[15] - The company is actively working with local government to manage its financial restructuring and improve its operational capabilities[15] Future Outlook - The company has not provided any guidance on future performance or new product developments in the recent conference call[15]
ST吉药(300108) - 2025 Q1 - 季度财报